An observational study in Hyperlipidemia, sponsored by Xin Li. Active, not recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Xin Li · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.
Among the 94 studies in Hyperlipidemias with a site in China, this one is the 2nd largest by enrollment of the 16 observational ones that give a count, is one of 14 that started in 2026, is one of 16 observational ones, reaches primary completion later than 16 of the 36 other live ones, and was the 94th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Jianyin Zhou · Sites in China
Ages 18–65
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 18–60
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 12 · Phase 3 20 · Phase 4 7
First in 2005; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42,088 is above the median of 320 across 101 observational studies indexed under Hyperlipidemias.
Median enrollment 155 across the 78 interventional studies, 1,151 across the 16 observational. Of the 44 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 94 have an industry lead sponsor. The 10 most frequent:
Xin Li is the lead sponsor of 3 studies on the registry; none are open to participants now.
Xin Li has 1 study filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
10 of the studies in Hyperlipidemias with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
| NCT07938099Xin LiReal-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hyperlipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a retrospective non-interventional cohort study, utilizing real-world administrative claim data and electronic health record data associated with the medical insurance database in Nanjing, China (2019-2026). The study aims to evaluate the real-world effectiveness and cost-effectiveness of PCSK9 monoclonal antibody(evolocumab, alirocumab, tafolecimab, ongericimab, recaticimab and ebronucimab) versus cholesterol absorption inhibitors (ezetimibe and hyzetimibe) as add-on lipid-lowering therapy in adults undergoing secondary prevention of atherosclerotic cardiovascular diseases (ASCVD). Outcomes include composite CVD, three-point major adverse cardiovascular events (MACE), fatal CVD, all-cause mortality, discontinuation, and persistence. Direct medical costs will be estimated from third-party payer and healthcare system perspectives. Cost-effectiveness will be expressed in terms of the incremental cost per prevented MACE), the number needed to treat (NNT), and the incremental cost per prevented all-cause death. Sensitivity analyses will assess robustness. Findings are intended to inform clinical selection, reimbursement, and dynamic adjustment of the medical insurance directory for ASCVD secondary prevention.
Patients with ASCVD remain at high risk of recurrent cardiovascular events despite statin therapy(lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin). Guidelines recommend intensifying lipid-lowering treatment with add-on agents such as PCSK9 monoclonal antibody or cholesterol absorption inhibitors when LDL-C goals are not achieved. PCSK9 monoclonal antibody produce large LDL-C reductions and have proven cardiovascular benefit in outcome trials, but their acquisition costs are substantially higher than those of ezetimibe. In Chinese real-world practice, treatment choice is influenced not only by efficacy and safety but also by affordability, reimbursement, adherence, and supply continuity. However, real-world comparative effectiveness and cost-effectiveness evidence directly comparing PCSK9i with CAIs in ASCVD secondary prevention remains limited. This study will use routinely collected data to complement trial-based evidence and support payer and clinical decision-making.
This retrospective cohort study will use de-identified linked data from regional medical insurance claims, electronic medical records, and death registry records in Nanjing, China, covering 1 Jan 2019 to 31 Aug 2026. As of the end of 2025, 8,960,800 people were enrolled in Nanjing's basic medical insurance program.
This study identified patients diagnosed between 2020 and August 31, 2026, with pure hypercholesterolemia, mixed hyperlipidemia, other hyperlipidemias, unstable angina, acute myocardial infarction, old myocardial infarction, other acute ischemic heart diseases, atherosclerotic heart disease, coronary artery aneurysms and coronary artery dissections, cerebral infarction, cerebral stroke (not specifically classified as hemorrhagic or ischemic), occlusion and stenosis of the pre-cerebral arteries, occlusion and stenosis of the cerebral arteries, atherosclerosis, and other peripheral vascular diseases.
This study will compare two treatment strategies: initiation of a PCSK9 monoclonal antibody versus initiation of a cholesterol absorption inhibitor, both in the context of combination statin therapy and without prior use of the other of these drugs. The index dates used in the baseline case-control analysis and sensitivity analysis are defined as the time when a patient began continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, and the time when a patient first discontinued continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, respectively. These two definitions of index dates are used to address study uncertainties that may arise from potential bias. Eligible patients were adults aged 40-85 years with secondary prevention for ASCVD (i.e., a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease). Patients who used PCSK9 monoclonal antibody or cholesterol absorption inhibitors consistently during this period were further identified. Consistent users were defined as patients who received a monthly refill of their medication for three consecutive months; in the PCSK9 monoclonal antibody group, this referred to refills of PCSK9 monoclonal antibody and statins, while in the cholesterol absorption inhibitor group, it referred to refills of cholesterol absorption inhibitors and statins. Stable users in both groups may have had multiple stable treatment regimens with the drug over time (in chronological order). Patients were followed up from the index date until death, loss to follow-up, occurrence of MACE, or August 31, 2026, whichever occurred first.
Direct medical costs will be measured from two perspectives: (1) third-party payer perspective, including reimbursed inpatient, outpatient, emergency, pharmacy, and procedure costs; and (2) healthcare system perspective, adding patient out-of-pocket payments. Costs will be adjusted for baseline healthcare expenditure and standardized to 2026 Chinese yuan. Effectiveness will be summarized using number NNT to prevent one MACE or one death. Incremental cost-effectiveness ratios (ICERs) will be calculated as the incremental adjusted cost per MACE avoided and, where feasible, as the incremental adjusted cost per QALY, using a Markov model based on real-world transition probabilities and published utility values. Results will be reported following the CHEERS 2022 checklist. The study is observational and non-interventional; no treatment will be assigned, and all analyses will use de-identified data with ethics approval.
Study participants will be selected from de-identified, linked regional health insurance reimbursement data, electronic health records, and death registration data from the Nanjing area of China, covering the time period from January 1, 2019, to August 31, 2026. The final cohort will be confirmed based on factors such as age, disease diagnosis, and history of medication exposure. Patient survival status information will be linked to the Bureau of Civil Affairs' resident death registration database. The source population includes approximately 8,960,800 people enrolled in Nanjing's basic medical insurance program as of the end of 2025. The study population will consist of adults aged 40-85 years with ASCVD receiving secondary prevention who newly initiated either a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor while on statin therapy and without prior use of the other of these drugs, and who met the consistent-user definition.
Adults aged 40-85 years who were diagnosed between 2020 and 31 August 2026 with pure hypercholesterolemia, mixed hyperlipidemia, other hyperlipidemias, or the specified ASCVD conditions (including unstable angina, acute myocardial infarction, old myocardial infarction, other acute ischemic heart disease, atherosclerotic heart disease, coronary artery aneurysm/dissection, cerebral infarction, stroke not specifically classified as hemorrhagic or ischemic, pre-cerebral/cerebral artery occlusion and stenosis, atherosclerosis, and other peripheral vascular diseases), and who were receiving secondary prevention for ASCVD (i.e., a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease), will be included. The age restriction of 40 to 85 years is intended to exclude patients with congenital, early-onset hypercholesterolemia-such as primary hypercholesterolemia and homozygous familial hypercholesterolemia-for whom secondary prevention is difficult. Eligible patients must have newly initiated a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor while receiving combination statin therapy, without prior use of the other of these drugs. The index dates used in the baseline case-control analysis and sensitivity analysis are defined as the time when a patient began continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, and the time when a patient first discontinued continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, respectively. Patients must be consistent users, defined as receiving a monthly refill for three consecutive months (PCSK9 monoclonal antibody plus statin in the PCSK9 monoclonal antibody group, or cholesterol absorption inhibitor plus statin in the cholesterol absorption inhibitor group).
PCSK9 monoclonal antibodies include evolocumab, alirocumab, t
Cholesterol absorption inhibitors included ezetimibe and hyzetimibe, and statins included lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. Exposure was identified through medical insurance reimbursement claims.
Major adverse cardiovascular events (MACE)
MACE includes myocardial infarction, stroke, recurrent angina pectoris, revascularization surgery, heart failure, severe arrhythmia, etc.
Time frame: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.
All-cause mortality
All-cause mortality refers to the total number of deaths caused by various factors within a certain period.
Time frame: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.
Plan to share: No — IPD will not be shared because the ethics committee approval and informed consent obtained for this retrospective study do not include permission for secondary data sharing with third parties.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.